Heart Failure

Medication adherence, the extent to which an individual’s behavior corresponds to a health care provider’s recommendations, remains an unaddressed challenge in health care.

Presence of CAD was prognostic of increased mortality for patients with heart failure, even for those with only mildly reduced ejection fraction, according a study published in the Journal of the American Heart Association.

Treatment with sodium-glucose cotransporter-2 inhibitors significantly lowered risks for lupus nephritis, dialysis and kidney transplant for patients with systemic lupus erythematosus and type 2 diabetes, according to data.

In patients with obesity-driven heart failure with preserved ejection fraction, semaglutide 2.4 mg was associated with more improvement in NYHA functional class compared with placebo, according to new data from the STEP-HFpEF trials.

Endotronix announced the FDA has given premarket approval to its pulmonary artery sensor system for the treatment of NYHA class III heart failure.

ORLANDO — Among adults with obesity-related heart failure with preserved ejection fraction, women taking semaglutide lost significantly more weight than men, but greater weight loss did not result in extra health benefits for women vs. men.

PHILADELPHIA — In this Healio video exclusive, Deepak L. Bhatt, MD, MPH, discusses two hot topics in cardiometabolic medicine: icosapent ethyl and sotagliflozin.

PHILADELPHIA — Early, cost-effective screening may predict and prevent incident heart failure events for patients with diabetes and no prior heart disease, a speaker reported.

Among older adults participating in the Systolic Blood Pressure Intervention Trial, a low eGFR without albuminuria was associated with a higher mortality rate but not with increased risk of cardiovascular events, results showed.